Mira Pharmaceuticals IncNASDAQ:MIRA
- LAST PRICE0.8598
- TODAY'S CHANGE (%)-0.0402 (-4.4667%)
- Bid / Lots0.8200/ 2
- Ask / Lots0.9000/ 1
- Open / Previous Close0.9171 / 0.9000
- Day Range
- 52 Week Range
- Volume12,903
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MIRA |
|---|---|---|
| 09:32 ET | 282 | 0.905 |
| 10:08 ET | 500 | 0.887499 |
| 10:10 ET | 500 | 0.9049 |
| 12:07 ET | 4900 | 0.87 |
| 01:46 ET | 800 | 0.87 |
| 01:48 ET | 426 | 0.86 |
| 02:49 ET | 2777 | 0.85 |
| 03:38 ET | 450 | 0.85 |
| 03:59 ET | 103 | 0.8598 |
Apr 2, 2024
DJ MIRA Pharmaceuticals Sees Positive Trial Results for Ketamir-2, from 8:17AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:17AM ET on Tuesday Apr 02, 2024 by Dow JonesMira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission, from 8:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mira Pharmaceuticals Inc | 12.7M | -1.0x | --- |
Microbot Medical Inc | 12.7M | -0.8x | --- |
NanoViricides Inc | 13.0M | -1.4x | --- |
Kiora Pharmaceuticals Inc | 12.3M | -0.2x | --- |
X T L Biopharmaceuticals Ltd | 13.1M | -4.8x | --- |
Alterity Therapeutics Ltd | 20.5M | -1.3x | --- |
Company Information
MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD). Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia.
Contact Information
- Headquarters
- 1200 Brickell Avenue, Suite 1950 #1183MIAMI, FL, United States 33131
- Phone
- 813-369-5150
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Erez Aminov
- Chief Financial Officer, Treasurer, Company Secretary
- Michelle Yanez
- Director
- Matthew Del Giudice
- Director
- Michael Jerman
- Director
- Ned Macpherson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 14.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.83 |
Book Value | $0.30 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
